NGM Biopharmaceuticals

About:

NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.

Website: http://www.ngmbio.com

Twitter/X: ngmbio

Top Investors: The Column Group, Merck, Rho Capital Partners, Topspin Partners, Prospect Venture Partners

Description:

NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

Total Funding Amount:

$542M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)ngmbio.com

Founders:

Jin-Long Chen

Number of Employees:

101-250

Last Funding Date:

2024-07-17

IPO Status:

Delisted

© 2025 bioDAO.ai